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PURPOSE: The purpose of this study was to compare the chondroprotective effect of diacerein and glucosamine regarding
degenerative changes and articular stiffness in an experimental model of arthritis.
METHODS: Twenty rats underwent medial meniscectomy on the right knee. Ten animals were given diacerhein, and 10 were
given glucosamine, from day 1 to the third month postoperatively, when all of them were killed. Histological and functional
analysis of the knees were performed (measurement of maximum extension).
RESULTS: All operated knees showed more limited extension values and more degenerative changes as compared to nonoperated
contralateral sides. A comparison of the two drugs showed that the degree of articular stiffness was significantly lower with
diacerein, although degenerative changes were similar.
CONCLUSIONS: 1) Prophylactic use of diacerein leads to lower degree of articular stiffness when compared to glucosamine; 2)
The prophylactic chondroprotective effects of diacerein and glucosamine are histologically similar.
KEYWORDS: Rats. Knee. Osteoarthritis. Anthraquinone. Meniscectomy. Glucosamine.
INTRODUCTION
Osteoarthritis (OA) is the most prevalent articular dis-
ease in the elderly.1 The process is characterized by changes
in the structure and function of the articulation, mainly due
to a degenerative process that takes place in the articular
cartilage.2
Destruction of articular cartilage results from a failure
of chondrocytes to maintain the balance between synthe-
sis and degradation of the extracellular cartilage matrix.
Proinflammatory cytokines, such as interleukin-1 (IL-1)
produced by macrophages, monocytes, synovial cells, and
chondrocytes play an important role in the development of
the disease.3
Currently, nonhormonal anti-inflammatory agents (such
as non steroidal anti-inflammatory drugs – NSAIDs), which
produce adverse reactions but do not change the disease’s
natural history,2,4-6 are used to relieve pain and inflamma-
tion.
Management of OA has been changed by the current
knowledge of the physiology and pharmacology of the ar-
ticular cartilage, as well as by the use of specific new drugs,
such as glucosamine,7 diacerein,8 and unsaponifiables.9
Diacerein is an anthraquinone derivative with an inhibi-
tory effect on production of cytokines by the synovial mem-
brane and chondrocytes, as well as on the bioactivity level
of IL-1 receptors.5
The aminomonosaccharide glucosamine is a major com-
ponent of the glucosaminoglycans in articular cartilage.7
Its effects include stimulation of physiologic proteoglycan
synthesis and decrease in the activity of catabolic enzymes
such as metalloproteases.2
A number of studies1-5,7,8,10-18 have shown that the use of
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diacerhein and of glucosamine is beneficial, because both
drugs reduce symptoms and change the articular structure
in OA.
OBJECTIVE
The purpose of this study was to functionally and
histologically compare the effect of diacerein to that of
glucosamine in an experimental rat model of OA.10
MATERIALS AND METHODS
The working material in this study consisted of 20 adult
male Wistar rats. The minimum number of animals required
to test the action of a potent drug is 4.10 We used 10 ani-
mals in each group to improve the safety margin.
The minimum age for inclusion was 8 weeks, and the
minimum weight was 180 grams. Rats older than 16 weeks
and weighing more than 390 grams were excluded.
All rats were anesthetized with halothane and under-
went total medial meniscectomy of the right knee as de-
scribed by Rezende.10
The surgical technique consisted of the following steps:
1) creation of a medial longitudinal access pathway, 2)
divulsion of the musculature of the medial knee aspect, 3)
sectioning of the medial collateral ligament, 4) total medial
meniscectomy, 5) suture of medial collateral ligament, and
6) suture of the musculature covering the medial collateral
ligament. Surgery was performed using a microscope.
The rats were divided into 2 groups as follows: Group
D, consisting of 10 rats that were given a 50-mg/kg/day
oral dose of diacerein from the first day to the third month
postoperative (PO), and Group G, consisting of 10 rats that
were given a 240-mg/kg/day oral dose of glucosamine dur-
ing the same period as Group D.
The two drugs were provided by supplying laboratories.
All rats were subjected to the same maintenance con-
ditions and were stimulated to walk freely.
In the third postoperative month, all animals were sub-
jected to euthanasia by intraperitoneal injection of ketamine
(10 mg/kg) plus twice the anesthetic dose of xylazine (6.4
mg/kg) to ensure painless death due to respiratory arrest.
Both knees of all animals were dissected from the cox-
ofemoral region to the ankle region, leaving the articular
capsule intact. After the dissection, the maximum exten-
sion angle of each knee was measured (Figure 1), with 0
degrees corresponding to the maximum possible extension.
In order to minimize any possible bias, all operations and
measurements of the extension level were performed by the
same surgeon.
The specimens were fixed in 10% formalin and submit-
ted to histological study. All knees were kept in this solu-
tion for 1 day and then demineralized in 7.5% nitric acid
for 2 to 3 days. After embedding the tissue in paraffin
blocks, tibial sections were prepared and stained with
hematoxylin-eosin and Alcian-blue. The articular cartilage
injuries found in the rats’ knees were evaluated and re-
corded using the Mankin score (Table 1) referred to by
Armstrong.4 In this system, the higher the score, the higher
the level of OA. The entire histological evaluation was per-
formed by the same pathologist. The histopathologist was
blindes to group distribution when this analysis was made.
A statistical analysis provided the mean values, stand-
ard deviation (SD), standard error of the mean (SEM),
maximum values (max), minimum values (min), and
number of cases (n).
We used the Wilcoxon test for paired samples and the
Mann-Whitney U-test for nonpaired samples. The level of
significance was set at 5% (a = 0.05).
Figure 1 - Measurement of maximum extension angle
Table 1 - The Mankin score
Variable Score
Surface 0 = normal
1 = irregular
2 = fibrillation / vacuoles
3 = blisters and erosion
Hypocellularity 0 = normal
1 = small decrease in chondrocytes
2 = large decrease in chondrocytes
3 = no cells
Clones 0 = normal
1 = occasional duos
2 = duos or trios
3 = multiple nested cells
Alcianophilia 0 = normal
1 = small decrease in color
2 = large decrease in color
3 = no color
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RESULTS
The functional analysis of each knee was performed by
analyzing the maximum extension angle (which reflects the
degree of articular stiffness according to the experimental
model, or the fixed flexion-extension of the knee), as shown
in Table 2. We found that the extension angle of
nonoperated knees for both groups was similar (25.6 de-
grees for the group receiving diacerein and 32.2 degrees
for the group receiving glucosamine, P = 0.18). The mean
extension angle of operated knees of the group receiving
diacerein (38.5 degrees) was statistically different from op-
erated knees of the group receiving glucosamine (54.1
degrees, P = 0.009) and different from their nonoperated
contralateral sides (25.6 degrees, P = 0.002). Operated
knees of rats receiving glucosamine were also statistically
different from their nonoperated controls (P = 0.003).
The histological analysis using the Mankin score
showed mild levels of degenerative changes in both oper-
ated and nonoperated knees of both groups. The operated
knees showed degenerative changes that were consistently
higher than their respective contralateral controls (P =
0.0195 for both groups) (Figures 2 and 3). The histologi-
cal scores of nonoperated sides of the groups receiving
diacerein (4.3) and glucosamine (3.8) were not significantly
different (P = 0.2). The levels of degenerative changes in
the meniscectomized sides for the groups receiving
diacerein (5.4) and glucosamine (6.6) were also similar (P
= 0.28), as shown in Table 3 and Figure 4.
DISCUSSION
In clinical studies and trials, the administration of
diacerein and glucosamine has produced a beneficial
Figure 2 - Diacerin group, case 1, Nonoperated knee (left). Mankin Score = 2 Figure 3 - Glucosamine group, case 5, operated knee (right). mankin score = 9
Table 2 - Evaluation of knee extension level, with 0 degrees corresponding to maximum extension
EXTENSION LEVEL
DIACEREIN - GROUP D GLUCOSAMINE - GROUP G
OPERATED NON-OPERATED OPERATED NON-OPERATED
MEAN 38.5 25.6 54.1 32.2
MAX 30 15 20 10
MIN 50 40 70 65
SD 7.84 7.68 15.40 14.25
SEM 2.48 2.56 4.76 4.50
n 10 10 10 10
Wilcoxon
P = 0.0020
Wilcoxon
P = 0.0029
Mann-Whitney
P = 0.0089
Mann-Whitney
P = 0.1823
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change in the structure of osteoarthritis, demonstrating a
chondroprotective efficacy that delays the progression of
the disease.1-7,9-17
Currently used NSAIDs act on symptoms only, have sig-
nificant side effects,2 mainly concerning the GI tract, and
there is evidence that these drugs induce accelerated pro-
gression of knee and hip arthritis.6 (it is not known whether
this occurs due to a direct harmful effect on the cartilage
or to increased mechanical overload after pain relief). Since
OA is a chronic disease, the use of NSAIDs is even more
limited. The drugs evaluated in the present study, on the
other hand, apart from acting on the symptoms, interfere
with the evolution of the disease itself, as mentioned; be-
cause they produce minimal side effects,1,2,10 they can be
administered for long periods. Both medications employed
in the present study have also been used in multicenter,
randomized, double-blind trials that employed each of these
drugs for long periods (up to 3 years), showing the delay
of arthritis progression1,13 with minimal side effects.
The fact that we were not able to find reports compar-
ing the use of diacerein and glucosamine led us to perform
the present study.
Regarding the prophylactic administration of a drug, we
were concerned with individuals (or animals, in the present
case) that had not yet presented arthritis. The disease would
appear due to ageing and stimulus (in this case, total me-
dial meniscectomy), and the aim here was to prevent such
degenerative changes by administering medications.
In this trial, diacerein was administered at a dose of 50
mg/kg/day, while glucosamine was administered at a dose
of 240 mg/kg/day; the doses are higher than those used in
humans because metabolic rates are higher in rats.
We chose the experimental model of Rezende10 because
it shows OA signs as early as 3 months postoperatively,
mainly on the tibial surface, which was the structure se-
lected for study in this trial. In addition to arthritis, this
experimental model leads to limited range of motion of the
knee, mainly concerning extension, because the access
pathway used in meniscectomy is relatively large for these
animals and because tibial collateral ligament sectioning
is required, followed by suture, causing stiffness due to fi-
brosis. We included extension in our analysis, considering
0 degree as maximum extension, ie, the lower the value,
the better the knee function.
The best functional results were observed with
diacerein, where the mean extension was 38.5°, while that
of glucosamine was 54.1°, which was significantly differ-
ent. This may be due to the interleukin-1-inhibiting power
of diacerein,3,5,14,15 which limits the fibrocicatricial process
Figure 4 - Level of histological changes of operated knees and nonoperated
knees receiving diacerein and glucosamine (Mankin score)
Table 3 - Evaluation by the Mankin score
THE MANKIN SCORE
DIACEREIN – GROUP DGLUCOSAMINE - GROUP G
OPERATED NON-OPERATED OPERATED NON-OPERATED
MEAN 5.4 4.3 6.6 3.8
MAX 7 6 10 10
MIN 3 2 1 0
SD 1.35 1.06 2.91 3.16
SEM 0.42 0.33 0.92 0.10
n 10 10 10 10
Wilcoxon
P = 0.0195
Wilcoxon
P = 0.0195
Mann-Whitney
P =.2799
Mann-Whitney
P = 0.2176
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during the perioperative period and leads to wider ranges
of motion. In vitro studies have shown that glucosamine
inhibits the effects of interleukin-1, although some authors
state that this inhibiting dose is greater than the maximum
serum dose of glucosamine (absorption limit).19, 20,21 Per-
haps, glucosamine at physiological dosages acts rather by
stimulating the production of matrix components than by
inhibiting the effects of interleukin-1. It still has to be de-
termined whether or not, in the long run, this limitation of
the range of motion in the rat group receiving glucosamine
would lead to major degenerative changes. Perhaps the
combination of glucosamine and chondroitin, already used
in humans,22,23 would provide better functional results, due
to the increased possibility of inhibiting the effects of
interleukin-1. Further studies are required to answer this
question.
When we compared operated and nonoperated knees,
we noticed different (significant) results both histologically
and functionally, which show that both diacerein and
glucosamine will not fully prevent degenerative changes
and articular stiffness after total medial knee meniscectomy.
However, the Mankin score in operated knees (5.4 in Group
D and 6.6 in Group G) shows mild levels of osteoarthritis
in both groups (maximum score: 12). This arthritis score
is lower than that found in previous studies where rats un-
derwent meniscectomy, but were not given drugs, and were
killed at 3 months postoperatively.10,19 This finding is also
valid for the nonoperated sides, with Mankin scores of 4.3
and 3.8, for Group D and G, respectively. Thus, the
nonoperated knees of both groups showed degenerative
changes that were lower than the expected value for the
animal’s age, which were a Mankin score of 5 in previous
trials in unmedicated animals, either due to overload on
the nonoperated knee or due to ageing.10,19
A histological comparison between the two drugs
showed similar results in the operated knees, as mentioned
above, with no significant differences. This trial had no con-
trol group because this had already been done in our Serv-
ice.19 Our study showed that diacerein can delay arthritis
secondary to meniscectomy and to ageing or overload of
the contralateral side.
The purpose of the present study was to explore whether
or not glucosamine has a chondroprotective effect similar
to that of diacerein. Although from the histological perspec-
tive, the effects appeared to be similar, from the functional
perspective, this was not the case, based on the range of
motion of the knee; treatment with diacerein was associ-
ated with a better range of motion of the operated knee than
that associated with treatment with glucosamine.
CONCLUSIONS
We conclude that prophylactic use of diacerein leads
to a lower degree of articular stiffness when compared to
glucosamine under conditions of experimentally induced
osteoarthritis; while the prophylactic chondroprotective ef-
fects of diacerein and glucosamine are histologically simi-
lar.
RESUMO
Rezende MU de, Gurgel HM de C, Vilaça Junior PR,
Kuroba RK, Lopes ASS, Phillipi RZ, et al. Diacereína x
glicosamina no modelo de artrose em ratos. CLINICS.
2006;61(5):461-6.
OBJETIVO: O trabalho foi realizado com o objetivo de
comparar o efeito condroprotetor da diacereína em relação
ao da glicosamina quanto às alterações degenerativas e à
rigidez articular num modelo experimental de artrose.
MÉTODOS: Vinte ratos foram submetidos à meniscec-
tomia medial do joelho direito. Dez animais receberam
diacereína, e dez glicosamina, todos do primeiro dia ao ter-
ceiro mês pós-operatório, quando foram sacrificados. Fo-
ram realizadas análise histológica e funcional (medida da
extensão máxima) dos joelhos.
RESULTADOS: Todos os joelhos operados apresentaram
amplitude de extensão mais limitada e maiores alterações
degenerativas, em relação ao lado contra-lateral não ope-
rado. Ao compararmos as duas drogas, a rigidez articular
foi significantemente menor com a diacereína, e as altera-
ções degenerativas foram semelhantes.
CONCLUSÕES: 1- O uso profilático da diacereína leva
à menor rigidez articular em relação a glicosamina. 2- O
efeito condroprotetor profilático da diacereína é semelhan-
te, histologicamente, ao da glicosamina.
UNITERMOS: Ratos. Joelho. Osteoartrite. Antraquinona.
Meniscectomia. Glicosamina.
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